Neoadjuvant therapy

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
7 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Antimetabolite 2 substances
CDK inhibitor 1 substance
Platinum compound 1 substance
Phase III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Centre Hospitalier Universitaire Rouen Academic
    CAPECITABINE; FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN
    2024-516456-17-00 1 country 2024 n=232
    Recruiting

Phase II

1 trial
  • F. Hoffmann-La Roche AG Commercial
    INAVOLISIB; LETROZOLE; RIBOCICLIB
    2024-518811-20-00 2 countries 2025 n=34
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Centre Hospitalier Universitaire Rouen Academic 1 Phase III 1
New trials by year
2024
1
2025
1
← All indication landscapes